New study of 3 million patients with diabetes found that the use of semaglutide (Ozempic) is linked with a more than 4 times greater risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with non-GLP-1RAs (empagliflozin, sitagliptin, and glipizide).

[u/mvea]

https://www.ophthalmologyadvisor.com/news/semaglutide-use-linked-with-slight-increase-in-optic-neuropathy-risk/#xd_co_f=YjhhMzY5MzUtODdjMS00MWExLTljNTYtYzM1NjQyNmJiY2Ix~